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We read with interest the article published by Selheim and
colleagues [1]. They demonstrate that activated platelets ex-
pose both VEGF receptors, Flt-1 and KDR. Katoh and col-
leagues have previously demonstrated the presence of the
mRNA of the VEGF receptor, KDR, in platelets and Salgado
and colleagues showed with immunoelectron microscopic
techniques that platelets might bind VEGF [2,3]. Selheim et
al. provide additional data supporting a role for VEGF in
enhancing thrombin-mediated platelet activation and aggrega-
tion. Their results add to the importance of platelet VEGF in
tumoural angiogenesis. Previous studies have demonstrated
that platelets of cancer patients acquire a higher VEGF load
parallel to tumour progression [3]. We elaborated on how
platelets acquire this higher VEGF load. Two mechanisms
were proposed: endocytosis of circulating VEGF, and/or en-
hanced VEGF production in the platelet precursors, the
megakaryocytes. The presence of VEGF on the platelet mem-
brane might suggest that endocytosis could occur since recep-
tor-mediated endocytosis of circulating proteins, e.g. ¢brin-
ogen, into the K-granules of platelets has been described.
We analysed the distribution of [125I]VEGF in the platelets
of ¢ve healthy individuals and ¢ve cancer patients after add-
ing [125I]VEGF to whole blood. Median counts per minute in
the platelet fraction was 50.9/103 platelets (S.D. 15.4) for the
cancer patients compared with 21.8/103 platelets (S.D. 8.4;
P=0.08, paired t-test) for the healthy persons, indicating en-
hanced VEGF binding on the platelets of the cancer patients.
As the authors noticed, activation of platelets exposes both
VEGF receptors. It is known that circulating platelets of can-
cer patients are activated, indicated by the increased expres-
sion of adhesion molecules on the platelet membrane and of
high circulating levels of platelet activation markers, e.g.
L-thromboglobulin, in the plasma of cancer patients [4].
This may account for a higher exposure of the VEGF recep-
tors on the membrane and thus for a higher probability of
scavenging circulating VEGF. It remains to be identi¢ed
whether membrane-bound VEGF, after transmitting signal-
ling into platelets, may also be endocytosed and transported
to the platelet K-granules accordingly. We did not succeed in
demonstrating incorporation of exogenously added VEGF to
platelet-rich plasma into platelets, which may be partly ex-
plained by incomplete activation of the platelets necessary
to express the VEGF receptors. On the other hand, we have
demonstrated that platelet VEGF may also be derived from
enhanced VEGF expression in platelet precursors, megakar-
yocytes, mediated by tumour-derived interleukin-6 (unpub-
lished data). Furthermore, immunohistochemistry for platelets
demonstrated adhesion and aggregation on tumoural endo-
thelium, which is invariably related to the release reaction of
VEGF [5]. We elaborated on the additional importance of the
higher platelet VEGF load in enhancing in an autocrine man-
ner the platelet activation, aggregation and thus local release
of VEGF at sites of coagulation, in this case tumours. A
higher platelet VEGF load is associated with fast tumour
growth kinetics and is associated with worse survival in pa-
tients with cancer [6]. The observations of Selheim and col-
leagues therefore add to the importance platelets can have in
intra-tumoural angiogenesis. Moreover, since anti-angiogenic
trials aimed at inhibiting the VEGF receptor tyrosine kinase
pathway are currently undergoing clinical trial, additional in-
direct anti-angiogenesis e¡ects might also be achieved by
blocking the MAPK and PI-3 kinase pathways in platelets.
Since these pathways are, as Selheim demonstrated, equally
involved in endothelial cells as well as platelets, blocking the
VEGF-mediated activation and aggregation may diminish the
intra-tumoural local release of platelet VEGF.
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